HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Suzanne Meeves Selected Research

fexofenadine (Allegra)

2/2007The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria.
10/2006Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies.
2/2006Efficacy of fexofenadine in the prophylactic control of cat allergen-induced allergic rhinitis.
6/2005Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.
9/2004Fexofenadine HCl 60 mg/ pseudoephedrine HCl 120 mg has a 60-minute onset of action in the treatment of seasonal allergic rhinitis symptoms, as assessed in an allergen exposure unit.
10/2003Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis.
7/2002Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Suzanne Meeves Research Topics

Disease

3Seasonal Allergic Rhinitis (Hay Fever)
10/2006 - 10/2003
2Chronic Urticaria
02/2007 - 06/2005
2Cough
10/2006 - 09/2004
2Allergic Rhinitis
02/2006 - 09/2004
2Rhinorrhea
02/2006 - 09/2004
2Sneezing
02/2006 - 09/2004
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
01/2022
1Pain (Aches)
05/2017
1Osteoporosis
10/2008
1Pruritus (Itching)
06/2005
1Headache (Headaches)
07/2002
1Hypersensitivity (Allergy)
07/2002

Drug/Important Bio-Agent (IBA)

7fexofenadine (Allegra)FDA LinkGeneric
02/2007 - 07/2002
4AllergensIBA
10/2006 - 07/2002
3PseudoephedrineFDA LinkGeneric
10/2006 - 07/2002
3Nasal Decongestants (Decongestants)IBA
10/2006 - 07/2002
2trans-sodium crocetinate (crocetin)IBA
10/2006 - 09/2004
2Histamine Antagonists (Antihistamines)IBA
10/2006 - 09/2004
1Dextroamphetamine (Dexedrine)FDA LinkGeneric
01/2022
1Ibuprofen (Motrin)FDA LinkGeneric
05/2017
1Naproxen (Naprosyn)FDA LinkGeneric
05/2017
1TabletsIBA
05/2017
1Delayed-Action PreparationsIBA
05/2017
1Analgesics (Analgesic Drugs)IBA
05/2017
1Teriparatide (Parathar)FDA Link
10/2008
1Risedronic Acid (Actonel)FDA LinkGeneric
10/2008
1Anabolic AgentsIBA
10/2008
1Alendronate (Alendronate Sodium)FDA LinkGeneric
10/2008
1Pharmaceutical PreparationsIBA
06/2005
1Cetirizine (Zyrtec)FDA LinkGeneric
10/2003
1Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)IBA
07/2002

Therapy/Procedure

1Therapeutics
10/2008